AGs Reach $272.5 Million Settlement of Opioid-Epidemic Related Claims Against Amneal Pharmaceuticals

Cozen O'Connor
Contact
LinkedIn
Facebook
X
Send
Embed

Cozen O'Connor

  • A coalition of AGs reached a settlement in principle with Amneal Pharmaceuticals, Inc., to resolve allegations that it contributed to the opioid epidemic in its role as a drug manufacturer.
  • According to the coalition, Amneal allegedly knowingly failed to monitor and report suspicious orders placed by its customers, as required by federal law.
  • Under the terms of the settlement in principle, the company must pay up to $92.5 million, and provide up to $180 million worth of naloxone nasal spray—an opioid antagonist that rapidly reverses the effects of an overdose—to participating states and local governments, with states that do not accept the medication receiving cash instead.
  • We have covered other AG actions related to the opioid epidemic, including Kentucky AG Russell Coleman’s lawsuit against Kroger Company and affiliated entities, Alaska AG Treg Taylor’s settlement with CVS, and two multistate AG settlements totaling $500 million with Publicis Health, LLC and Hikma Pharmaceuticals.
Send Print Report

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Cozen O'Connor | Attorney Advertising

Written by:

Cozen O'Connor
Cozen O'Connor
Contact
more
less

PUBLISH YOUR CONTENT ON JD SUPRA NOW

  • Increased visibility
  • Actionable analytics
  • Ongoing guidance

Cozen O'Connor on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign Up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide